Summary
The problem: Today the complex and time-critical therapeutic decision in Acute Ischaemic Stroke (AIS) relies on the availability of expert stroke radiologists. However, only 5% of hospitals have facilities meeting the standards of comprehensive stroke centres. Thus, for 95% of hospitals, optimal treatment cannot be quickly identified and safely commenced. Consequently, only about 30% of AIS patients receive specialized stroke unit care across Europe.
The solution: iTrust is a clinical decision support (CDS) software that uses Convolutional Neural Networks to predict the outcome of treatment strategies in AIS, based on the patient’s biomarkers as well as clinical information, including brain scan images. The prediction shown as high-resolution images of probable brain tissue outcomes in function of each treatment available.
The market: Revenue from the iTrust software will come as annual licences fees: a model clearly preferred according to the surveyed KOLs. Initially, the distribution of the software will be carried out through strategic partnerships (formal agreements already signed) with the major medical scanner (CT, MRI) vendors, which will allow us to exploit their global sale channels and large installed base. The total addresable market for iTrust is over EUR 430 million per year in OECD countries. Given the high incidence of AIS, low volume (5%) of hospitals prepared to initiate the treatment and the high importance of quickly allocating the appropriate therapeutic intervention, we estimate an accumulated turnover exceeding EUR 41 million of the iTrust solution, five years post-project.
The solution: iTrust is a clinical decision support (CDS) software that uses Convolutional Neural Networks to predict the outcome of treatment strategies in AIS, based on the patient’s biomarkers as well as clinical information, including brain scan images. The prediction shown as high-resolution images of probable brain tissue outcomes in function of each treatment available.
The market: Revenue from the iTrust software will come as annual licences fees: a model clearly preferred according to the surveyed KOLs. Initially, the distribution of the software will be carried out through strategic partnerships (formal agreements already signed) with the major medical scanner (CT, MRI) vendors, which will allow us to exploit their global sale channels and large installed base. The total addresable market for iTrust is over EUR 430 million per year in OECD countries. Given the high incidence of AIS, low volume (5%) of hospitals prepared to initiate the treatment and the high importance of quickly allocating the appropriate therapeutic intervention, we estimate an accumulated turnover exceeding EUR 41 million of the iTrust solution, five years post-project.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/859165 |
| Start date: | 01-05-2019 |
| End date: | 31-10-2021 |
| Total budget - Public funding: | 2 616 250,00 Euro - 1 831 375,00 Euro |
Cordis data
Original description
The problem: Today the complex and time-critical therapeutic decision in Acute Ischaemic Stroke (AIS) relies on the availability of expert stroke radiologists. However, only 5% of hospitals have facilities meeting the standards of comprehensive stroke centres. Thus, for 95% of hospitals, optimal treatment cannot be quickly identified and safely commenced. Consequently, only about 30% of AIS patients receive specialized stroke unit care across Europe.The solution: iTrust is a clinical decision support (CDS) software that uses Convolutional Neural Networks to predict the outcome of treatment strategies in AIS, based on the patient’s biomarkers as well as clinical information, including brain scan images. The prediction shown as high-resolution images of probable brain tissue outcomes in function of each treatment available.
The market: Revenue from the iTrust software will come as annual licences fees: a model clearly preferred according to the surveyed KOLs. Initially, the distribution of the software will be carried out through strategic partnerships (formal agreements already signed) with the major medical scanner (CT, MRI) vendors, which will allow us to exploit their global sale channels and large installed base. The total addresable market for iTrust is over EUR 430 million per year in OECD countries. Given the high incidence of AIS, low volume (5%) of hospitals prepared to initiate the treatment and the high importance of quickly allocating the appropriate therapeutic intervention, we estimate an accumulated turnover exceeding EUR 41 million of the iTrust solution, five years post-project.
Status
CLOSEDCall topic
EIC-SMEInst-2018-2020Update Date
27-10-2022
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
